Cerebrospinal Fluid Biomarkers in Psychiatric Autoimmune Encephalitis: a Retrospective Cohort Study

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2023 Jun 26

PMID 37363167

Authors

Niels Hansen

Aaron Levin Juhl

Insa Maria Grenzer

Bianca Teegen

Jens Wiltfang

Dirk Fitzner

Affiliations

Soon will be listed here.

Abstract

Background: Psychiatric autoimmune encephalitis (pAE) is a growing field of interest in diagnosis and therapy in psychiatric hospitals and institutions. This study investigates the relevant extent to which there are potential biomarkers in cerebrospinal fluid (CSF) that can differentiate against a cohort with neurodegenerative disease.

Methods: We included in this study a total of 27 patients with possible and definite psychiatric autoimmune encephalitis and compared with a cohort with CSF-based AD ( = 27) different biomarkers in CSF such as lactate, cell count, % lymphocytes, % monocytes, total protein content, albumin, immunoglobulins G (IgG), M (IgM) and A (IgA), CSF/serum albumin ratio, CSF/serum IgG ratio, CSF/serum IgA ratio, intrathecal IgG synthesis, blood-brain barrier disruption, specific antibody synthesis for measles, rubella, herpes simplex virus, varicella zoster virus, Ebstein-Barr virus and cytomegalovirus, total tau protein (t-tau), phosphorylated tau protein 181 (p-tau181), amyloid beta 42 (Aß42), amyloid beta 40 (Aß40) and the amyloid beta 42/ amyloid beta 40 (Aß42/40) ratio.

Results: The p-tau 181 was elevated above cut-off values in both possible pAE and AD. However, in definitive pAE, p-tau181 levels were not elevated. When elevated p-tau181 levels in possible AE were compared with those in AD, we found relevant differences, such as a relative increase in p-tau181 in AD patients. Elevated p-tau181 levels were detected in possible psychiatric AEs with IgLON5, glycine, recoverin, titin, and nonspecific neuropil antibodies in serum and IgLON5, titin, Yo, and nonspecific neuropil autoantibodies in CSF. In addition, we detected elevated levels of p-tau181 and IgLON5 autoantibodies in serum and CSF, and Yo autoantibodies in CSF in patients with definitive pAE. Interestingly, we observed a higher CSF/serum IgM ratio in possible and definitive pAE than in AD patients.

Conclusion: Our results suggest that neuroaxonal brain damage may occur in specific psychiatric AEs associated with IgLON5, glycine, recoverin, and titin autoantibodies. Further research should focus on the CSF/serum IgM ratio as an early marker of autoantibody production in pAE compared to AD as a potential biomarker for differential diagnosis.

References

Whitson H, Colton C, El Khoury J, Gate D, Goate A, Heneka M . Infection and inflammation: New perspectives on Alzheimer's disease. Brain Behav Immun Health. 2022; 22:100462. PMC: 9475126. DOI: 10.1016/j.bbih.2022.100462. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

Constantinescu R, Krysl D, Bergquist F, Andren K, Malmestrom C, Asztely F . Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. Eur J Neurol. 2016; 23(4):796-806. DOI: 10.1111/ene.12942. View

Dubois B, Villain N, Frisoni G, Rabinovici G, Sabbagh M, Cappa S . Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021; 20(6):484-496. PMC: 8339877. DOI: 10.1016/S1474-4422(21)00066-1. View

Hansen N, Juhl A, Grenzer I, Hirschel S, Teegen B, Fitzner D . Cerebrospinal Fluid Total Tau Protein Correlates With Longitudinal, Progressing Cognitive Dysfunction in Anti-Neural Autoantibody-Associated Dementia and Alzheimer's Dementia: A Case-Control Study. Front Immunol. 2022; 13:837376. PMC: 8927820. DOI: 10.3389/fimmu.2022.837376. View

Nass R, Akgun K, Elger C, Reichmann H, Wagner M, Surges R . Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: An exploratory study. Seizure. 2020; 85:1-5. DOI: 10.1016/j.seizure.2020.12.009. View

Flanagan E, Geschwind M, Lopez-Chiriboga A, Blackburn K, Turaga S, Binks S . Autoimmune Encephalitis Misdiagnosis in Adults. JAMA Neurol. 2022; 80(1):30-39. PMC: 9706400. DOI: 10.1001/jamaneurol.2022.4251. View

Banks S, Sechi E, Flanagan E . Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. Ther Adv Neurol Disord. 2021; 14:1756286421998906. PMC: 7983436. DOI: 10.1177/1756286421998906. View

Bulbarelli A, Lonati E, Brambilla A, Orlando A, Cazzaniga E, Piazza F . Aβ42 production in brain capillary endothelial cells after oxygen and glucose deprivation. Mol Cell Neurosci. 2012; 49(4):415-22. DOI: 10.1016/j.mcn.2012.01.007. View

10.

Piazza F, Caminiti S, Zedde M, Presotto L, DiFrancesco J, Pascarella R . Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies. Neurology. 2022; 99(12):e1265-e1277. PMC: 9576297. DOI: 10.1212/WNL.0000000000200892. View

11.

Li Y, Rusinek H, Butler T, Glodzik L, Pirraglia E, Babich J . Decreased CSF clearance and increased brain amyloid in Alzheimer's disease. Fluids Barriers CNS. 2022; 19(1):21. PMC: 8919541. DOI: 10.1186/s12987-022-00318-y. View

12.

DeMarshall C, Viviano J, Emrani S, Thayasivam U, Godsey G, Sarkar A . Early Detection of Alzheimer's Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers. J Alzheimers Dis. 2023; 92(3):1077-1091. PMC: 10116135. DOI: 10.3233/JAD-221091. View

13.

Piazza F, Greenberg S, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I . Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol. 2013; 73(4):449-58. DOI: 10.1002/ana.23857. View

14.

Antolini L, DiFrancesco J, Zedde M, Basso G, Arighi A, Shima A . Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study. Neurology. 2021; 97(18):e1809-e1822. PMC: 8610623. DOI: 10.1212/WNL.0000000000012778. View

15.

Bastiaansen A, van Steenhoven R, de Bruijn M, Crijnen Y, van Sonderen A, van Coevorden-Hameete M . Autoimmune Encephalitis Resembling Dementia Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021; 8(5). PMC: 8362342. DOI: 10.1212/NXI.0000000000001039. View

16.

Hansen N, Juhl A, Grenzer I, Rentzsch K, Wiltfang J, Fitzner D . Prevalence of Anti-neural Autoantibodies in a Psychiatric Patient Cohort-Paradigmatic Application of Criteria for Autoimmune-Based Psychiatric Syndromes. Front Psychiatry. 2022; 13:864769. PMC: 9196031. DOI: 10.3389/fpsyt.2022.864769. View

17.

Graus F, Titulaer M, Balu R, Benseler S, Bien C, Cellucci T . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15(4):391-404. PMC: 5066574. DOI: 10.1016/S1474-4422(15)00401-9. View

18.

Cai W, Li L, Sang S, Pan X, Zhong C . Physiological Roles of β-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology. Neurosci Bull. 2022; 39(8):1289-1308. PMC: 10387033. DOI: 10.1007/s12264-022-00985-9. View

19.

Chang B, Day G, Graff-Radford J, McKeon A, Flanagan E, Algeciras-Schimnich A . Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis. Eur J Neurol. 2022; 29(10):2905-2912. PMC: 9463096. DOI: 10.1111/ene.15469. View

20.

Leng F, Edison P . Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?. Nat Rev Neurol. 2020; 17(3):157-172. DOI: 10.1038/s41582-020-00435-y. View